Iberdomide

Iberdomide.svg

Iberdomide.svg

Iberdomide (development code: CC-220) is an immunomodulatory drug that is being investigated for the treatment of various autoimmune diseases and hematologic malignancies. It is a derivative of thalidomide and belongs to the class of drugs known as cereblon modulators.

Mechanism of Action

Iberdomide exerts its effects by binding to the cereblon protein, which is part of the E3 ubiquitin ligase complex. This binding leads to the degradation of specific target proteins, including Ikaros and Aiolos, which are transcription factors involved in the regulation of immune response and cell proliferation. By modulating the levels of these proteins, iberdomide can alter the activity of immune cells and inhibit the growth of cancer cells.

Clinical Development

Iberdomide is currently undergoing clinical trials for the treatment of several conditions, including systemic lupus erythematosus (SLE), multiple myeloma, and myelodysplastic syndromes. Early-phase studies have shown promising results in terms of efficacy and safety, but further research is needed to confirm these findings and determine the optimal dosing regimens.

Side Effects

As with other immunomodulatory drugs, iberdomide may cause a range of side effects. Common adverse effects observed in clinical trials include neutropenia, thrombocytopenia, and gastrointestinal disturbances. Patients receiving iberdomide should be monitored regularly for these and other potential side effects.

See Also

• Thalidomide
• Lenalidomide
• Pomalidomide
• Cereblon
• Immunomodulatory drugs

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian